Zuclopenthixol decanoate depot

Extrapyramidal reactions may occur, especially during the first few days after injection and in the early phase of treatment. In most cases these side effects can be satisfactorily controlled by reduction of dosage and/or use of antiparkinsonian drugs. The routine prophylactic use of antiparkinsonian drugs is not recommended. Antiparkinsonian drugs do not alleviate tardive dyskinesia and may aggravate them. Reduction in dosage or, if possible, discontinuation of flupentixol decanoate therapy is recommended. In persistent akathisia, a benzodiazepine or propranolol may be useful.

Elderly patients with dementia-related psychosis treated with atypical antipsychotic drugs are at an increased risk of death compared to placebo. Although the causes of death in clinical trials were varied, most of the deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Observational studies suggest that antipsychotic drugs may increase mortality. It is unclear from these studies to what extent the mortality findings may be attributed to the antipsychotic drug as opposed to patient characteristics. Haloperidol is not approved for the treatment of patients with dementia-related psychosis .

Zuclopenthixol decanoate depot

zuclopenthixol decanoate depot

Media:

zuclopenthixol decanoate depotzuclopenthixol decanoate depotzuclopenthixol decanoate depotzuclopenthixol decanoate depotzuclopenthixol decanoate depot

http://buy-steroids.org